ValuEngine downgraded shares of Cutera (NASDAQ:CUTR) from a buy rating to a hold rating in a research report released on Monday.

A number of other research firms have also weighed in on CUTR. BidaskClub lowered shares of Cutera from a buy rating to a hold rating in a research note on Thursday, September 20th. Stephens reduced their price objective on shares of Cutera from $40.00 to $24.94 and set a sell rating for the company in a research note on Friday, October 5th. Stifel Nicolaus reduced their price objective on shares of Cutera from $45.00 to $29.00 and set a hold rating for the company in a research note on Friday, October 5th. Sidoti set a $50.00 price objective on shares of Cutera and gave the company a buy rating in a research note on Friday, October 5th. Finally, Zacks Investment Research upgraded shares of Cutera from a strong sell rating to a hold rating in a research note on Wednesday, December 5th. Three analysts have rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the company. Cutera presently has a consensus rating of Hold and a consensus price target of $39.24.

NASDAQ:CUTR traded down $0.17 on Monday, reaching $14.19. 5,735 shares of the stock traded hands, compared to its average volume of 290,796. The firm has a market cap of $191.60 million, a P/E ratio of 18.48 and a beta of 1.03. Cutera has a 12 month low of $12.32 and a 12 month high of $56.05.

Cutera (NASDAQ:CUTR) last released its quarterly earnings data on Tuesday, November 6th. The medical device company reported $0.11 earnings per share for the quarter, beating analysts’ consensus estimates of $0.03 by $0.08. The business had revenue of $40.60 million during the quarter, compared to analyst estimates of $40.03 million. Cutera had a net margin of 11.16% and a negative return on equity of 0.50%. Cutera’s revenue was up 6.4% compared to the same quarter last year. During the same period last year, the business earned $0.42 EPS. Sell-side analysts anticipate that Cutera will post -0.29 EPS for the current fiscal year.

Several hedge funds have recently made changes to their positions in CUTR. Rhumbline Advisers grew its stake in shares of Cutera by 5.8% in the second quarter. Rhumbline Advisers now owns 32,824 shares of the medical device company’s stock worth $1,323,000 after acquiring an additional 1,812 shares during the period. SG Americas Securities LLC bought a new stake in Cutera during the second quarter valued at approximately $154,000. Schwab Charles Investment Management Inc. grew its position in Cutera by 51.6% during the second quarter. Schwab Charles Investment Management Inc. now owns 44,976 shares of the medical device company’s stock valued at $1,813,000 after buying an additional 15,304 shares during the period. BlueMountain Capital Management LLC grew its position in Cutera by 44.8% during the second quarter. BlueMountain Capital Management LLC now owns 9,139 shares of the medical device company’s stock valued at $368,000 after buying an additional 2,828 shares during the period. Finally, Laurion Capital Management LP bought a new stake in Cutera during the second quarter valued at approximately $766,000. Hedge funds and other institutional investors own 93.36% of the company’s stock.

About Cutera

Cutera, Inc, a medical device company, designs, develops, manufactures, markets, and services laser and other energy based aesthetics systems worldwide. The company offers enlighten platform, a laser system that is used for tattoo removal, as well as for the treatment of benign pigmented lesions; excel HR platform, a hair removal solution for various skin types; and truSculpt, a high-powered radio frequency platform designed for deep tissue heating.

Read More: What are Institutional Investors?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Cutera (NASDAQ:CUTR)

Receive News & Ratings for Cutera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cutera and related companies with MarketBeat.com's FREE daily email newsletter.